Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 10/2022

05.09.2022 | Spondyloarthritiden | Meilensteine der Rheumatologie

Geschichte der Biologikatherapie bei axialer Spondyloarthritis – Teil 1

verfasst von: Prof. J. Braun, Prof. J. Sieper

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Dies ist eine persönliche Geschichte von zwei befreundeten Berliner Rheumatologen, die in den 1980er-Jahren im Berliner Universitätsklinikum Benjamin Franklin (UKBF, früher Klinikum Steglitz) zusammen arbeiteten und sich entschlossen, klinisch und wissenschaftlich rheumatologisch tätig zu werden: Joachim Sieper und Jürgen Braun (Abb. 1).
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Beide Firmen gibt es heute nicht mehr (sie wurden von Johnson & Johnson (Janssen) 1999 bzw. von Merck 2009 übernommen).
 
Literatur
1.
Zurück zum Zitat Sieper J, Kingsley G, Palacios-Boix A, Pitzalis C, Treharne J, Hughes R, Keat A, Panayi GS (1991) Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter’s disease. Arthritis Rheum 34(5):588–598CrossRef Sieper J, Kingsley G, Palacios-Boix A, Pitzalis C, Treharne J, Hughes R, Keat A, Panayi GS (1991) Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter’s disease. Arthritis Rheum 34(5):588–598CrossRef
2.
Zurück zum Zitat Sieper J, Braun J, Brandt J, Miksits K, Heesemann J, Laitko S, Sorensen H, Distler A, Kingsley G (1992) Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. J Rheumatol 19(8):1236–1242 Sieper J, Braun J, Brandt J, Miksits K, Heesemann J, Laitko S, Sorensen H, Distler A, Kingsley G (1992) Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. J Rheumatol 19(8):1236–1242
3.
Zurück zum Zitat Braun J, Sieper J, Schwarz A, Keller F, Heitz J, von Ameln H (1991) Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)—successful treatment with cyclophosphamide pulse followed by plasmapheresis. Br J Rheumatol 30(4):312–313CrossRef Braun J, Sieper J, Schwarz A, Keller F, Heitz J, von Ameln H (1991) Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)—successful treatment with cyclophosphamide pulse followed by plasmapheresis. Br J Rheumatol 30(4):312–313CrossRef
4.
Zurück zum Zitat Braun J, Sieper J, Schulte KL, Thiel E, Janitschke K (1991) Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. Clin Rheumatol 10(4):445–448CrossRef Braun J, Sieper J, Schulte KL, Thiel E, Janitschke K (1991) Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. Clin Rheumatol 10(4):445–448CrossRef
5.
Zurück zum Zitat Bollow M, Braun J, König H, Schilling A, Wacker F, Seyrekbasan VF, Eggens U, Wolf KJ (1994) Dynamische Magnetresonanztomographie der Sakroiliakalgelenke: Erkennung von Frühstadien einer Sakroiliitis. Rontgenpraxis 47(3):70–77 Bollow M, Braun J, König H, Schilling A, Wacker F, Seyrekbasan VF, Eggens U, Wolf KJ (1994) Dynamische Magnetresonanztomographie der Sakroiliakalgelenke: Erkennung von Frühstadien einer Sakroiliitis. Rontgenpraxis 47(3):70–77
6.
Zurück zum Zitat Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37(7):1039–1045CrossRef Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37(7):1039–1045CrossRef
7.
Zurück zum Zitat Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505CrossRef Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505CrossRef
8.
Zurück zum Zitat Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A, Distler A, Sieper J (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664 Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A, Distler A, Sieper J (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664
9.
Zurück zum Zitat Braun J, Tuszewski M, Eggens U, Mertz A, Schauer-Petrowskaja C, Döring E, Laitko S, Distler A, Sieper J, Ehlers S (1997) Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. J Rheumatol 24(6):1092–1100 Braun J, Tuszewski M, Eggens U, Mertz A, Schauer-Petrowskaja C, Döring E, Laitko S, Distler A, Sieper J, Ehlers S (1997) Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. J Rheumatol 24(6):1092–1100
10.
Zurück zum Zitat Braun J, Tuszewski M, Ehlers S, Häberle J, Bollow M, Eggens U, Distler A, Sieper J (1997) Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol 24(6):1101–1105 Braun J, Tuszewski M, Ehlers S, Häberle J, Bollow M, Eggens U, Distler A, Sieper J (1997) Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol 24(6):1101–1105
11.
Zurück zum Zitat Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59(2):135–140CrossRef Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59(2):135–140CrossRef
12.
Zurück zum Zitat François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65(6):713–720CrossRef François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65(6):713–720CrossRef
13.
Zurück zum Zitat Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352CrossRef Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352CrossRef
14.
Zurück zum Zitat Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193CrossRef Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193CrossRef
15.
Zurück zum Zitat Brandt J, Haibel H, Sieper J, Reddig J, Braun J (2001) Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 44(12):2936–2937CrossRef Brandt J, Haibel H, Sieper J, Reddig J, Braun J (2001) Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 44(12):2936–2937CrossRef
16.
Zurück zum Zitat Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444 (Erratum in: Arthritis Res Ther 2005;7(3):113)CrossRef Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444 (Erratum in: Arthritis Res Ther 2005;7(3):113)CrossRef
17.
Zurück zum Zitat Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345CrossRef Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345CrossRef
18.
Zurück zum Zitat Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9):1690–1699CrossRef Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9):1690–1699CrossRef
19.
Zurück zum Zitat van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Ankylosing spondylitis study for the evaluation of recombinant Infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591CrossRef van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Ankylosing spondylitis study for the evaluation of recombinant Infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591CrossRef
20.
Zurück zum Zitat Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29(1):118–122 Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29(1):118–122
21.
Zurück zum Zitat Deodhar A, Strand V, Kay J, Braun J (2016) The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 75(5):791–794CrossRef Deodhar A, Strand V, Kay J, Braun J (2016) The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 75(5):791–794CrossRef
22.
Zurück zum Zitat Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451CrossRef Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451CrossRef
23.
Zurück zum Zitat Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647CrossRef Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647CrossRef
24.
Zurück zum Zitat Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670CrossRef Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670CrossRef
25.
Zurück zum Zitat Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281CrossRef Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281CrossRef
26.
Zurück zum Zitat Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444CrossRef Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444CrossRef
27.
Zurück zum Zitat Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J (2007) Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34(3):510–515 Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J (2007) Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34(3):510–515
28.
Zurück zum Zitat Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824CrossRef Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824CrossRef
29.
Zurück zum Zitat Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904CrossRef Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904CrossRef
30.
Zurück zum Zitat Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67CrossRef Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67CrossRef
31.
Zurück zum Zitat Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24(4):697–735CrossRef Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24(4):697–735CrossRef
32.
Zurück zum Zitat Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136CrossRef Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136CrossRef
33.
Zurück zum Zitat Baraliakos X, Landewé R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J (2005) Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64(5):730–734CrossRef Baraliakos X, Landewé R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J (2005) Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64(5):730–734CrossRef
34.
Zurück zum Zitat Baraliakos X, Kruse S, Auteri SE, de Peyrecave N, Nurminen T, Kumke T, Hoepken B, Braun J (2022) Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4‑year post-hoc MRI results from a phase 3 study. Rheumatology (Oxford) 61(7):2875–2885CrossRef Baraliakos X, Kruse S, Auteri SE, de Peyrecave N, Nurminen T, Kumke T, Hoepken B, Braun J (2022) Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4‑year post-hoc MRI results from a phase 3 study. Rheumatology (Oxford) 61(7):2875–2885CrossRef
35.
Zurück zum Zitat Rudwaleit M, Jurik AG, Hermann KG, Landewé R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527CrossRef Rudwaleit M, Jurik AG, Hermann KG, Landewé R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527CrossRef
36.
Zurück zum Zitat Baraliakos X, Hermann KG, Landewé R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J (2005) Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64(8):1141–1144CrossRef Baraliakos X, Hermann KG, Landewé R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J (2005) Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64(8):1141–1144CrossRef
37.
Zurück zum Zitat Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J (2020) Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years. Ann Rheum Dis 79(2):186–192CrossRef Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J (2020) Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years. Ann Rheum Dis 79(2):186–192CrossRef
38.
Zurück zum Zitat Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J (2021) Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? Ann Rheum Dis 80(4):469–474CrossRef Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J (2021) Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? Ann Rheum Dis 80(4):469–474CrossRef
39.
Zurück zum Zitat Baraliakos X, Ghadir A, Fruth M, Kiltz U, Redeker I, Braun J (2021) Which magnetic resonance imaging lesions in the sacroiliac joints are most relevant for diagnosing axial spondyloarthritis? A prospective study comparing rheumatologists’ evaluations with radiologists’ findings. Arthritis Rheumatol 73(5):800–805CrossRef Baraliakos X, Ghadir A, Fruth M, Kiltz U, Redeker I, Braun J (2021) Which magnetic resonance imaging lesions in the sacroiliac joints are most relevant for diagnosing axial spondyloarthritis? A prospective study comparing rheumatologists’ evaluations with radiologists’ findings. Arthritis Rheumatol 73(5):800–805CrossRef
40.
Zurück zum Zitat Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104CrossRef Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104CrossRef
41.
Zurück zum Zitat Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J (2014) Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 73(10):1819–1825CrossRef Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J (2014) Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 73(10):1819–1825CrossRef
42.
Zurück zum Zitat Baraliakos X, Boehm H, Bahrami R, Samir A, Schett G, Luber M, Ramming A, Braun J (2019) What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Ann Rheum Dis 78(9):1220–1225CrossRef Baraliakos X, Boehm H, Bahrami R, Samir A, Schett G, Luber M, Ramming A, Braun J (2019) What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Ann Rheum Dis 78(9):1220–1225CrossRef
43.
Zurück zum Zitat van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070CrossRef van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070CrossRef
44.
Zurück zum Zitat Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450–1453CrossRef Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450–1453CrossRef
45.
Zurück zum Zitat Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B (2014) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73(6):1107–1113CrossRef Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B (2014) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73(6):1107–1113CrossRef
46.
Zurück zum Zitat Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B (2016) Serum C‑reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol 43(9):1704–1712CrossRef Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B (2016) Serum C‑reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol 43(9):1704–1712CrossRef
47.
Zurück zum Zitat Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73(4):710–715CrossRef Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73(4):710–715CrossRef
48.
Zurück zum Zitat Braun J, Sieper J (2008) What is the most important outcome parameter in ankylosing spondylitis? Rheumatology (Oxford) 47(12):1738–1740CrossRef Braun J, Sieper J (2008) What is the most important outcome parameter in ankylosing spondylitis? Rheumatology (Oxford) 47(12):1738–1740CrossRef
49.
Zurück zum Zitat Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470CrossRef Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470CrossRef
50.
Zurück zum Zitat Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J (2016) Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF‑α inhibitors for up to 10 years. J Rheumatol 43(12):2142–2148CrossRef Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J (2016) Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF‑α inhibitors for up to 10 years. J Rheumatol 43(12):2142–2148CrossRef
Metadaten
Titel
Geschichte der Biologikatherapie bei axialer Spondyloarthritis – Teil 1
verfasst von
Prof. J. Braun
Prof. J. Sieper
Publikationsdatum
05.09.2022
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 10/2022
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-022-01262-w

Weitere Artikel der Ausgabe 10/2022

Zeitschrift für Rheumatologie 10/2022 Zur Ausgabe

Einführung zum Thema

Rheuma und Niere

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.